A drug binding to a receptor is just the first step. The real question is, what happens next? Two key properties govern this interaction: affinity and intrinsic activity. Think of them as separate but related concepts.

Affinity is the measure of how tightly a drug binds to a receptor. A drug with high affinity will bind strongly and stay bound, even at low concentrations. It's a measure of attraction.

Intrinsic activity, on the other hand, describes the ability of a drug to activate the receptor and produce a biological response once it's bound. It measures the drug's effectiveness as a messenger.

Intrinsic activity isn't an all-or-nothing property. Drugs exist on a spectrum, defined by how they modulate a receptor's function.

• Full Agonists: These drugs have high intrinsic activity. They bind to and activate receptors to their maximum capacity, producing the strongest possible biological response.

• Partial Agonists: These have intermediate intrinsic activity. Even if they occupy every single available receptor, they cannot produce a maximal response. Their effect is always submaximal compared to a full agonist. This can be useful therapeutically; for example, buprenorphine is a partial agonist at opioid receptors, providing pain relief with a lower risk of respiratory depression than full agonists like morphine.

• Inverse Agonists: This is where things get interesting. Some receptors have a baseline level of activity even without any agonist bound, a state known as constitutive activity and its presence forms the two-state model of receptor activation. An inverse agonist binds to these receptors and stabilizes them in an inactive state, reducing this baseline activity. It doesn't just block a signal; it actively dials it down below its normal resting state.

When an agonist binds and activates a receptor, it kicks off a chain reaction inside the cell called signal transduction. The initial signal, the drug binding, is amplified into a much larger cellular response. One of the most common and important mechanisms involves G-protein coupled receptors (GPCRs).

When a ligand binds to a GPCR, the receptor changes shape. This conformational change allows it to activate a G-protein on the inner surface of the cell membrane. The activated G-protein then interacts with other enzymes or channels.

A common target is the enzyme adenylyl cyclase. When activated, it converts ATP into cyclic AMP (cAMP). This [{]}, known as a second messenger, spreads throughout the cell, activating other proteins like protein kinases, which in turn phosphorylate and modify the function of numerous other cellular proteins. This cascade effect means a single receptor binding event can have a widespread and amplified impact on cell function.

We can visualize and quantify a drug's effect using a dose-response curve, which plots the magnitude of the response against the drug concentration. From this curve, we can determine two critical parameters: efficacy and potency.

Efficacy ($E_{max}$) is the maximum response a drug can produce. It's represented by the plateau of the dose-response curve. A full agonist has high efficacy, while a partial agonist has lower efficacy.

Potency ($EC_{50}$) is the concentration of a drug required to produce 50% of its maximal effect. A lower $EC_{50}$ value means the drug is more potent; a smaller amount is needed to achieve the same half-maximal effect. Potency is about concentration, while efficacy is about the maximum possible effect.

By analyzing these curves, we can compare drugs directly. A drug shifted to the left is more potent. A drug with a lower plateau is less efficacious. This quantitative approach is fundamental to pharmacology, allowing scientists to predict how a drug will behave in a biological system and to design medications with precisely tuned effects.